{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:17:45Z","timestamp":1790853465524,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"the Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte"},{"DOI":"10.13039\/501100008208","name":"the Overl\u00e6ge Johan Boserup og Lise Boserups Legat","doi-asserted-by":"publisher","award":["20795-24"],"award-info":[{"award-number":["20795-24"]}],"id":[{"id":"10.13039\/501100008208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015223","name":"the Danish Diabetes and Endocrine Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Danish Cardiovascular Academy"},{"DOI":"10.13039\/501100009708","name":"the Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22SA0079901"],"award-info":[{"award-number":["NNF22SA0079901"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"the Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF20SA0067242"],"award-info":[{"award-number":["NNF20SA0067242"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"the Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF20SA0064340"],"award-info":[{"award-number":["NNF20SA0064340"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the BRIDGE-Translational Excellence Programme"},{"DOI":"10.13039\/501100006442","name":"the Faculty of Health and Medical Sciences, University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"The Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["4285-00212B"],"award-info":[{"award-number":["4285-00212B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Elevated remnant cholesterol is a causal factor for atherosclerotic cardiovascular disease (ASCVD); however, whether aggressive lowering will reduce ASCVD is unclear. In women and men, we tested the hypothesis that aggressive lowering of remnant cholesterol has the potential for substantial ASCVD reduction. This was tested using modelling of cohort data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>From the Copenhagen General Population Study, 56 422 women and 43 952 men without a history of ASCVD were recruited from 2003 through 2015. They were subsequently followed in national Danish health registries until December 2021 for incident ASCVD. During a median follow-up of 12 years, 4946 women and 6043 men developed ASCVD. In women at very-high cardiovascular risk, 2\u2005mmol\/L (77\u2005mg\/dL) lower levels of remnant cholesterol from 3\u2005mmol\/L (116\u2005mg\/dL) likely reduces absolute 10-year risk of ASCVD by 17 and 13% in statin users and non-users; corresponding values in men were 20 and 15%, respectively. Corresponding values by 1\u2005mmol\/L (39\u2005mg\/dL) lower remnant cholesterol were 10 and 7% in women and 11 and 9% in men, respectively. Similar values are also provided for lower starting remnant cholesterol levels, different lowering of remnant cholesterol, and lower baseline cardiovascular risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In women and men, aggressive lowering of remnant cholesterol has the potential for substantial ASCVD reduction. Estimated absolute risk reduction was larger in statin users vs. non-users and in men vs. women, likely because statin users vs. non-user and men vs. women are at higher baseline absolute risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf203","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:59:10Z","timestamp":1744063150000},"page":"1145-1154","source":"Crossref","is-referenced-by-count":13,"title":["Remnant cholesterol reduction for atherosclerotic cardiovascular disease prevention: modelling in the Copenhagen General Population Study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4889-2679","authenticated-orcid":false,"given":"Karen","family":"Hvid","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2014 Herlev and Gentofte , Borgmester Ib Juuls vej 73, 2730 Herlev ,","place":["Denmark"]},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital , Borgmester Ib Juuls Vej 73, Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-2298","authenticated-orcid":false,"given":"Mie","family":"Balling","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2014 Herlev and Gentofte , Borgmester Ib Juuls vej 73, 2730 Herlev ,","place":["Denmark"]},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital , Borgmester Ib Juuls Vej 73, Herlev ,","place":["Denmark"]},{"name":"Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen , \u00d8ster Farimagsgade 5, 1353 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-4694","authenticated-orcid":false,"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2014 Herlev and Gentofte , Borgmester Ib Juuls vej 73, 2730 Herlev ,","place":["Denmark"]},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital , Borgmester Ib Juuls Vej 73, Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, 2200 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2014 Herlev and Gentofte , Borgmester Ib Juuls vej 73, 2730 Herlev ,","place":["Denmark"]},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital , Borgmester Ib Juuls Vej 73, Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, 2200 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025092119524408200_zwaf203-B1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"2025092119524408200_zwaf203-B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2025092119524408200_zwaf203-B3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis"},{"key":"2025092119524408200_zwaf203-B4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","article-title":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the Multi-Ethnic Study of Atherosclerosis","volume":"11","author":"Wong","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025092119524408200_zwaf203-B5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2025092119524408200_zwaf203-B6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2025092119524408200_zwaf203-B7","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.25432","article-title":"Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population","volume":"85","author":"Varbo","year":"2019","journal-title":"Ann Neurol"},{"key":"2025092119524408200_zwaf203-B9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"2025092119524408200_zwaf203-B10","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B11","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2022","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B12","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119524408200_zwaf203-B13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025092119524408200_zwaf203-B14","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B15","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurjpc\/zwad036","article-title":"Remnant cholesterol, low-density lipoprotein cholesterol, and incident cardiovascular disease among Koreans: a national population-based study","volume":"30","author":"Lee","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119524408200_zwaf203-B17","first-page":"1169","article-title":"High remnant cholesterol and atherosclerotic cardiovascular disease in healthy women and men aged 70\u2013100","volume":"32","author":"Riis","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119524408200_zwaf203-B18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092119524408200_zwaf203-B19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092119524408200_zwaf203-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B21","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025092119524408200_zwaf203-B23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2025092119524408200_zwaf203-B24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u2005mg\/dL (105\u2005nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025092119524408200_zwaf203-B25","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"2025092119524408200_zwaf203-B26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/clinchem\/hvae046","article-title":"Worldwide increasing use of nonfasting rather than fasting lipid profiles","volume":"70","author":"Langsted","year":"2024","journal-title":"Clin Chem"},{"key":"2025092119524408200_zwaf203-B27","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"2025092119524408200_zwaf203-B28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2025092119524408200_zwaf203-B29","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025092119524408200_zwaf203-B31","first-page":"535","article-title":"The Danish Cancer Registry\u2013history, content, quality and use","volume":"44","author":"Storm","year":"1997","journal-title":"Dan Med Bull"},{"key":"2025092119524408200_zwaf203-B32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish Cancer Registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"2025092119524408200_zwaf203-B33","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B34","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"Vries","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2025092119524408200_zwaf203-B36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2025092119524408200_zwaf203-B37","author":"Gray","year":"2022"},{"key":"2025092119524408200_zwaf203-B38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a010013","article-title":"Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies","volume":"150","author":"Clarke","year":"1999","journal-title":"Am J Epidemiol"},{"key":"2025092119524408200_zwaf203-B39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"2025092119524408200_zwaf203-B40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"2025092119524408200_zwaf203-B41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025092119524408200_zwaf203-B42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2025092119524408200_zwaf203-B43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Bor\u00e9n","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2025092119524408200_zwaf203-B44","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"2025092119524408200_zwaf203-B45","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025092119524408200_zwaf203-B46","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-023-06016-0","article-title":"Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study","volume":"66","author":"Wadstr\u00f6m","year":"2023","journal-title":"Diabetologia"},{"key":"2025092119524408200_zwaf203-B47","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","article-title":"Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort study","volume":"44","author":"El\u00edas-L\u00f3pez","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025092119524408200_zwaf203-B48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","article-title":"Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study","volume":"64","author":"Varbo","year":"2018","journal-title":"Clin Chem"},{"key":"2025092119524408200_zwaf203-B49","volume-title":"The Metabolic & Molecular Bases of Inherited Disease","author":"Scriver","year":"2001"},{"issue":"Supplemental 1","key":"2025092119524408200_zwaf203-B50","article-title":"Remnant cholesterol lowering in cardiovascular disease risk reduction in statin trials: meta-regression analyses","volume":"45","author":"Nordestgaard","year":"2024","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092119524408200_zwaf203-B52","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","article-title":"Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u03b2, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"2025092119524408200_zwaf203-B54","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","article-title":"Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial","volume":"31","author":"Zimerman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119524408200_zwaf203-B55","first-page":"1","article-title":"Expanding the triglyceride range in clinical trials: therapeutic opportunities","author":"Nordestgaard","year":"2025","journal-title":"Eur Heart J"},{"key":"2025092119524408200_zwaf203-B56","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025092119524408200_zwaf203-B57","doi-asserted-by":"crossref","first-page":"117556","DOI":"10.1016\/j.atherosclerosis.2024.117556","article-title":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","volume":"393","author":"Doi","year":"2024","journal-title":"Atherosclerosis"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf203\/62886919\/zwaf203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1145\/62886919\/zwaf203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1145\/62886919\/zwaf203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:52:53Z","timestamp":1758498773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/32\/13\/1145\/8107979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":57,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf203","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,8]]}}}